Tumor Mutational Load, CD8+T Cells, Expression of PD-L1 and HLA Class I to Guide Immunotherapy Decisions

被引：1
|
作者：
Hurkmans, D. [1 ]
Kuipers, M. [2 ]
Smit, J. [2 ]
Van Marion, R. [3 ]
Mathijssen, R. [4 ]
Postmus, P. [2 ]
Hiemstra, P. [2 ]
Aerts, J. [1 ]
Von der Thusen, J. [3 ]
Van der Burg, S. [5 ]
机构：
[1] Erasmus Univ, Med Ctr, Pulmonol, Rotterdam, Netherlands
[2] Leiden Univ, Med Ctr, Pulmonol, Leiden, Netherlands
[3] Erasmus Univ, Med Ctr, Pathol, Rotterdam, Netherlands
[4] Erasmus Univ, Med Ctr, Med Oncol, Rotterdam, Netherlands
[5] Leiden Univ, Med Ctr, Med Oncol, Leiden, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
immune checkpoint inhibitor; NSCLC; predictive biomarkers;
D O I：
10.1016/j.jtho.2019.08.1552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-47
引用
收藏
页码：S726 / S726
页数：1
相关论文
共 50 条
  • [41] Loss of tumor HLA class I and PD-L1 expression in bladder cancer is associated with higher tumor grade and poor survival prognosis
    Gil-Julio, Hernani
    Perea, Francisco
    Torres, Cristina
    Manuel Cozar, Jose
    Garrido, Federico
    Aptsiauri, Natalia
    Ruiz-Cabello, Francisco
    HLA, 2022, 99 (05) : 448 - 449
  • [42] Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells
    Tu, Jingyao
    Xu, Haoran
    Ma, Li
    Li, Chunya
    Qin, Wan
    Chen, Xinyi
    Yi, Ming
    Sun, Li
    Liu, Bo
    Yuan, Xianglin
    THERANOSTICS, 2022, 12 (02): : 747 - 766
  • [43] Potential Influence of MHC Class I Expression in Uterine Carcinosarcomas on the Outcome of PD-L1 Immunotherapy
    Jones, Terri
    Bhargava, Rohit
    Soong, Thing Rinda
    Elishaev, Esther
    Jones, Mirka
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 700 - 700
  • [44] Potential Influence of MHC Class I Expression in Uterine Carcinosarcomas on the Outcome of PD-L1 Immunotherapy
    Jones, Terri
    Bhargava, Rohit
    Soong, Thing Rinda
    Elishaev, Esther
    Jones, Mirka
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 700 - 700
  • [45] Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8+T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer
    Shuai, Chong
    Yang, Xinmei
    Pan, Hongming
    Han, Weidong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [46] Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
    Iwai, Y
    Ishida, M
    Tanaka, Y
    Okazaki, T
    Honjo, T
    Minato, N
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (19) : 12293 - 12297
  • [47] PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
    Sabbatino, Francesco
    Villani, Vincenzo
    Yearley, Jennifer H.
    Deshpande, Vikram
    Cai, Lei
    Konstantinidis, Ioannis T.
    Moon, Christina
    Nota, Sjoerd
    Wang, Yangyang
    Al-Sukaini, Ahmad
    Zhu, Andrew X.
    Goyal, Lipika
    Ting, David T.
    Bardeesy, Nabeel
    Hong, Theodore S.
    Castillo, Carlos Fernandez-Del
    Tanabe, Kenneth K.
    Lillemoe, Keith D.
    Ferrone, Soldano
    Ferrone, Cristina R.
    CLINICAL CANCER RESEARCH, 2016, 22 (02) : 470 - 478
  • [48] Intratumoral programmed cell death-ligand 1 (PD-L1) and Intratumoral CD8+T cell Expression in Lung Cancer
    Jin, Yasuto
    Yamauchi, Shuta
    Shimada, Hiroyuki
    Matsubara, Osamu
    CANCER SCIENCE, 2018, 109 : 1099 - 1099
  • [49] Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignancies
    Thawani, Rajat
    Kartika, Thomas
    Elstrott, Benjamin
    Batiuk, Elizabeth
    Tao, Derrick
    Gowda, Sonia
    Chen, Lilian
    Lavasseur, Corinne
    Tun, Nattapron
    Taflin, Nicholas F.
    Shatzel, Joseph
    THROMBOSIS RESEARCH, 2022, 217 : 12 - 14
  • [50] Tumor-draining lymph node-derived tumor-specific memory CD8+ T cells: a key player in PD-1/PD-L1 immunotherapy
    Enzhi Yin
    Nan Sun
    Jie He
    Signal Transduction and Targeted Therapy, 8
12345